Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-cell RNA-sequencing of murine intestine 24 hours following acute p53 activation due to Mdm2-loss (Mdm2FM/- Cag-CreERTg (FMTg)) compared to intestine that retain Mdm2 (Mdm2+/- Cag-CreERTg (Tg))

ABSTRACT: single-cell RNA-sequencing of murine intestine 24 hours following acute p53 activation due to Mdm2-loss (Mdm2FM/- Cag-CreERTg (FMTg)) compared to intestine that retain Mdm2 (Mdm2+/- Cag-CreERTg (Tg))

PROVIDER: PRJNA639792 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12023949_1.fastq.gz	Fastqsanger.gz
	SRR12023949_2.fastq.gz	Fastqsanger.gz
	SRR12023950_1.fastq.gz	Fastqsanger.gz
	SRR12023950_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

single-cell RNA-sequencing of murine intestine 24 hours following acute p53 activation due to Mdm2-loss (Mdm2FM/- Cag-CreERTg (FMTg)) compared to intestine that retain Mdm2 (Mdm2+/- Cag-CreERTg (Tg))

Project description:FMTg (Mdm2FM/- Cag-CreERTg) and Tg (Mdm2+/- Cag-CreERTg) mice were administered 6mg/40g of Tamoxifen dissolved in corn-oil and sacrificed 24 hours after injection. Single cells were isolated from fresh small intestine samples to compare single cell transcriptomes between intestine with high or control p53 activity

2020-08-24 | GSE152587 | GEO

RNA-sequencing of mice 24 hours following acute p53 activation due to Mdm2-loss (Mdm2FM/- Cag-CreERTg (FMTg)) compared to mice that retain Mdm2 (Mdm2+/- Cag-CreERTg (Tg))

Project description:FMTg (Mdm2FM/- Cag-CreERTg) and Tg (Mdm2+/- Cag-CreERTg) mice were administered 6mg/40g of Tamoxifen dissolved in corn-oil and sacrificed 24 hours after injection. Tissues were flash frozen and RNA was isolated using TriZOL reagent as per manufacturers protocols. The goal of this study is to understand the differences and similarities between the p53 transcriptome in various murine tissues

2020-08-24 | GSE151571 | GEO

RNA-sequencing of mice 24 hours following acute p53 activation due to Mdm2-loss (Mdm2FM/- Cag-CreERTg (FMTg)) compared to mice that retain Mdm2 (Mdm2+/- Cag-CreERTg (Tg))

Project description:RNA-sequencing of mice 24 hours following acute p53 activation due to Mdm2-loss (Mdm2FM/- Cag-CreERTg (FMTg)) compared to mice that retain Mdm2 (Mdm2+/- Cag-CreERTg (Tg))

| PRJNA636385 | ENA

Transcription profiling of intestine from wild type and Mdm2 knock-out mice

Project description:Analyzed gene expression in 3-day old mice lacking Mdm2 in the intestine

2008-03-23 | E-MEXP-1431 | biostudies-arrayexpress

Transcriptome analysis of CD229 OE (CAG-OE) and WT(CAG-WT) in CAG

Project description:Transcriptome sequencing was used to analyze changes in related signaling pathways and gene expression in CAG cells when CD229 was overexpressed.

2022-12-14 | GSE199200 | GEO

Genome-wide maps of chromatin binding site for Mdm2.

Project description:The MDM2 oncoprotein is an essential component of the p53 pathway. Although MDM2 has been widely described as a major negative regulator of the p53 tumor suppressor, growing evidences support the notion that Mdm2 functions are also mediated through p53 independent mechanisms. We found that MDM2 is recruited on chromatin. By ChIP-Seq (using MDM2 antibody) of H1299 cells exhibiting MDM2 recruitment on chromatin, we identified at the whole genome level MDM2 binding sites. Both input and IPped-DNA were exhaustively sequenced and mapped on human genome

2016-06-09 | GSE64439 | GEO

Transcriptome analysis of CD229 OE (CAG-OE) and WT(CAG-WT) in CAG

Project description:Transcriptome analysis of CD229 OE (CAG-OE) and WT(CAG-WT) in CAG

| PRJNA818871 | ENA

Development of MDM2-targeting PROTAC technology for advancing bone regeneration

Project description:MDM2 inhibitor remarkably induced biomineralization in hDPSCs but it remained the problem that p53 activation is insufficient due to MDM2-p53 autoregulatory feedback loop. To overcome the limitation of the MDM2 inhibitors, we applied proteolysis targeting chimera (PROTAC), a technology that degrades a protein of interest (POI) by intracellular ubiquitin-proteasome system. Hence, we propose a strategy to induce hard tissue regeneration by MDM2-targeting PROTAC technology. We selected Nutlin-3 of POI ligand among various MDM2 inhibitors based on the screening process, and the selected CRBN of E3 ligase ligand. The MDM2-PROTAC synthesis platform was designed by each ligand combination. By performing the degradation test for selected compounds, we evaluated the characteristics of the developed MDM2 PROTAC such as the maximal degradation concentration (DCmax), the half of maximal degradation concentration (DC50), and half-lifetime. To investigate gene expression profiling of MDM2-targeting small molecules, we conducted RNA-sequencing under MDM2 PROTAC and Nutlin-3 (POI ligand) treated conditions. We not only confirmed a robust effect on biomineralization by MDM2-targeting small molecules but also demonstrated the potent osteogenic differentiation ability of MDM2 PROTAC when compared to an MDM2 inhibitor. MDM2-PROTAC significantly increased mRNA levels of osteogenic differentiation marker genes. Also, the significant bone generation effect of MDM2 PROTAC was validated in an ovariectomy (OVX)-induced osteoporosis animal model. Through these results, it is expected that a new therapeutic modality for hard tissue regeneration will be possible, and the application range of the PROTAC system can be expanded.

2024-06-11 | GSE255297 | GEO

Low CAG promoter activity enriches for reprogramming progressive cells

Project description:The variability in reprogramming propensity is associated with the activity of the MKL1/SRF transcription factor and concurs with small cell size as well as rapid cell cycle. Reprogramming progressive cells can be prospectively identified by their low activity of a widely used synthetic promoter, CAG. CAG low cells arise and expand during cell cycle acceleration in the early reprogramming culture of both mouse and human fibroblasts. Here, CAG low and CAG high cells from reprogramming culture were FACS-sorted and subject to RNA-sequencing. Data support the notion that Low CAG promoter activity enriches for reprogramming progressive cells. Our work illustrates a molecular scenario underlying the distinct reprogramming propensities and demonstrates a convenient practical approach for their enrichment.

2020-11-01 | GSE157672 | GEO

CDK4 inhibition diminishes p53 activation by Mdm2-antagonists

Project description:CDK4 inhibitors have reached clinical approval for cancer therapy. In parallel, the p53 antagonist Mdm2 remains an attractive target for anti-cancer therapy, including numerous clinical studies. The genes encoding Mdm2 and CDK4 are frequently co-amplified in human malignancies, most notably in liposarcomas, suggesting their combined targeting for therapy. Here we show, however, that small compounds that inhibit Mdm2 and CDK4 antagonize each other rather than synergize in their cytotoxicity towards sarcoma cells. CDK4 inhibition attenuates the induction of p53-responsive genes upon Mdm2 inhibition, and similar results were obtained when depleting Mdm2 and/or CDK4 with siRNA. CDK4 inhibitors also interfered with p53 activity in response to DNA damage. CDK4 inhibition did not reduce p53 binding or histone acetylation to promoters, but rather attenuated the subsequent recruitment of RNA polymerase II. The complexes of p53 and Mdm2, as well as CDK4 and Cyclin D1, physically associated with each other. Upon combined inhibition of Mdm2 and CDK4/6, the interaction of this complex was impaired. Thus, the CDK4-Cyclin D1 complex plays a key role in enabling the transcription of p53 target genes. Taken together, our results raise caution regarding the combination of CDK4 inhibitors with Mdm2 antagonists or conventional DNA-damaging chemotherapeutics in the clinics. Moreover, they suggest a hitherto unknown role for CDK4-cyclin D1 complex in sustaining p53 activity, possibly focusing p53-mediated transcription on actively proliferating cells.

2018-09-20 | GSE113369 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data